FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2017101410> ?p ?o ?g. }

• W2017101410 endingPage "157" @default.
• W2017101410 startingPage "148" @default.
• W2017101410 abstract "Patients with urgency urinary incontinence (UUI) due to overactive bladder (OAB) refractory to oral antimuscarinics have limited therapeutic options. OnabotulinumtoxinA appears to be an effective new treatment.Assess disease-specific quality-of-life outcomes and general health-related quality-of-life (HRQOL) outcomes following treatment with onabotulinumtoxinA in patients with idiopathic OAB and UUI inadequately managed with antimuscarinics.A phase 2, randomized, double-blind, placebo-controlled, dose-ranging study conducted at 40 sites from July 2005 to June 2008 with 313 patients (288 females) with idiopathic OAB experiencing eight or more UUI episodes per week and eight or more micturitions per day at baseline, with follow-up of 36 wk.Intradetrusor onabotulinumtoxinA (50 U, 100 U, 150 U, 200 U, or 300 U) or placebo.HRQOL was assessed using the urinary Incontinence-Specific Quality-of-Life Instrument (I-QOL), the King's Health Questionnaire (KHQ) symptom component, and the Medical Outcomes Study 36-Item Short-Form Health Survey. Descriptive statistics were used for absolute scores/changes from baseline. Within-group changes from baseline were assessed using paired t tests. Change from baseline for each onabotulinumtoxinA group compared with placebo was analyzed using an analysis of covariance model.OnabotulinumtoxinA treatment at doses≥100 U produced significantly greater improvements than placebo in the I-QOL total and subscale scores at all follow-up visits from week 2 through week 24 (p<0.05). OnabotulinumtoxinA doses≥100 U produced significantly greater improvements than placebo in the KHQ symptom score at a majority of follow-up visits. HRQOL instruments demonstrated low to moderate correlations (Spearman correlation range: 0.01-0.51) with the symptoms of UUI recorded using daily diary data, with I-QOL demonstrating the highest correlations. A study limitation was that certain quality-of-life measures were exploratory and not validated.A single onabotulinumtoxinA treatment with doses≥100 U resulted in statistically significant and clinically meaningful improvement in HRQOL by week 2 compared with placebo, and this improvement was sustained for ≤36 wk in patients with idiopathic OAB and UUI who were inadequately managed by oral antimuscarinics.ClinicalTrials.gov identifier: NCT00168454." @default.
• W2017101410 created "2016-06-24" @default.
• W2017101410 creator A5000710049 @default.
• W2017101410 creator A5008438464 @default.
• W2017101410 creator A5015064871 @default.
• W2017101410 creator A5018101112 @default.
• W2017101410 creator A5018766684 @default.
• W2017101410 creator A5030853743 @default.
• W2017101410 creator A5040084332 @default.
• W2017101410 creator A5064978476 @default.
• W2017101410 creator A5074097027 @default.
• W2017101410 creator A5090151123 @default.
• W2017101410 date "2012-07-01" @default.
• W2017101410 modified "2023-10-16" @default.
• W2017101410 title "OnabotulinumtoxinA Improves Health-Related Quality of Life in Patients With Urinary Incontinence Due to Idiopathic Overactive Bladder: A 36-Week, Double-Blind, Placebo-Controlled, Randomized, Dose-Ranging Trial" @default.
• W2017101410 cites W1483144760 @default.
• W2017101410 cites W1599498888 @default.
• W2017101410 cites W1967347194 @default.
• W2017101410 cites W1994178716 @default.
• W2017101410 cites W1998207473 @default.
• W2017101410 cites W2009593049 @default.
• W2017101410 cites W2013089245 @default.
• W2017101410 cites W2013407887 @default.
• W2017101410 cites W2046590607 @default.
• W2017101410 cites W2064865346 @default.
• W2017101410 cites W2076929508 @default.
• W2017101410 cites W2079232828 @default.
• W2017101410 cites W2084355008 @default.
• W2017101410 cites W2094970779 @default.
• W2017101410 cites W2130226970 @default.
• W2017101410 cites W2131173377 @default.
• W2017101410 cites W2141005094 @default.
• W2017101410 cites W2155335951 @default.
• W2017101410 cites W2157993246 @default.
• W2017101410 cites W2172057491 @default.
• W2017101410 cites W4292806894 @default.
• W2017101410 doi "https://doi.org/10.1016/j.eururo.2012.03.005" @default.
• W2017101410 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/22464310" @default.
• W2017101410 hasPublicationYear "2012" @default.
• W2017101410 type Work @default.
• W2017101410 sameAs 2017101410 @default.
• W2017101410 citedByCount "70" @default.
• W2017101410 countsByYear W20171014102012 @default.
• W2017101410 countsByYear W20171014102013 @default.
• W2017101410 countsByYear W20171014102014 @default.
• W2017101410 countsByYear W20171014102015 @default.
• W2017101410 countsByYear W20171014102016 @default.
• W2017101410 countsByYear W20171014102017 @default.
• W2017101410 countsByYear W20171014102018 @default.
• W2017101410 countsByYear W20171014102019 @default.
• W2017101410 countsByYear W20171014102020 @default.
• W2017101410 countsByYear W20171014102021 @default.
• W2017101410 countsByYear W20171014102022 @default.
• W2017101410 countsByYear W20171014102023 @default.
• W2017101410 crossrefType "journal-article" @default.
• W2017101410 hasAuthorship W2017101410A5000710049 @default.
• W2017101410 hasAuthorship W2017101410A5008438464 @default.
• W2017101410 hasAuthorship W2017101410A5015064871 @default.
• W2017101410 hasAuthorship W2017101410A5018101112 @default.
• W2017101410 hasAuthorship W2017101410A5018766684 @default.
• W2017101410 hasAuthorship W2017101410A5030853743 @default.
• W2017101410 hasAuthorship W2017101410A5040084332 @default.
• W2017101410 hasAuthorship W2017101410A5064978476 @default.
• W2017101410 hasAuthorship W2017101410A5074097027 @default.
• W2017101410 hasAuthorship W2017101410A5090151123 @default.
• W2017101410 hasConcept C126322002 @default.
• W2017101410 hasConcept C126894567 @default.
• W2017101410 hasConcept C142724271 @default.
• W2017101410 hasConcept C159110408 @default.
• W2017101410 hasConcept C168563851 @default.
• W2017101410 hasConcept C1862650 @default.
• W2017101410 hasConcept C204787440 @default.
• W2017101410 hasConcept C27081682 @default.
• W2017101410 hasConcept C2776312127 @default.
• W2017101410 hasConcept C2778531004 @default.
• W2017101410 hasConcept C2778941218 @default.
• W2017101410 hasConcept C2779951463 @default.
• W2017101410 hasConcept C2991744798 @default.
• W2017101410 hasConcept C535046627 @default.
• W2017101410 hasConcept C71924100 @default.
• W2017101410 hasConcept C77411442 @default.
• W2017101410 hasConceptScore W2017101410C126322002 @default.
• W2017101410 hasConceptScore W2017101410C126894567 @default.
• W2017101410 hasConceptScore W2017101410C142724271 @default.
• W2017101410 hasConceptScore W2017101410C159110408 @default.
• W2017101410 hasConceptScore W2017101410C168563851 @default.
• W2017101410 hasConceptScore W2017101410C1862650 @default.
• W2017101410 hasConceptScore W2017101410C204787440 @default.
• W2017101410 hasConceptScore W2017101410C27081682 @default.
• W2017101410 hasConceptScore W2017101410C2776312127 @default.
• W2017101410 hasConceptScore W2017101410C2778531004 @default.
• W2017101410 hasConceptScore W2017101410C2778941218 @default.
• W2017101410 hasConceptScore W2017101410C2779951463 @default.
• W2017101410 hasConceptScore W2017101410C2991744798 @default.
• W2017101410 hasConceptScore W2017101410C535046627 @default.
• W2017101410 hasConceptScore W2017101410C71924100 @default.
• W2017101410 hasConceptScore W2017101410C77411442 @default.
• W2017101410 hasFunder F4320332585 @default.

• next